Valeant/Ono deal gives new option for rare disorder in Japan
This article was originally published in Scrip
Executive Summary
Metyrosine may have been launched in the US back in the late 1970s, but an official review in Japan last year identified an outstanding medical need for the tyrosine hydroxylase inhibitor for the treatment of pheochromocytoma.